Yahoo · Sep 4, 2026
Envista (NVST) Up 0.8% Since Last Earnings Report: Can It Continue?
Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NE
NASDAQ · NEOG
Neogen Corporation
Healthcare · Medical - Diagnostics & Research
$11.78
Up+$0.01 (+0.08%)
Updated Sep 12, 2026, 7:25 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.53B
- P/E ratio
- -1.47
- Dividend yield
- 0.00%
- 52-week range
- $8.16 – $12.85
- Volume
- 1.67M
- Avg. volume
- 5.04M
Price performance
NEOG price history
1M range · 20 trading sessions · Daily adjusted prices
NEOG closed at $11.78 after 20 trading sessions, up 1.12% for the selected period.
- Last close
- $11.78
- Period change
- +1.12%
- Period low
- $11.56
- Period high
- $12.15
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $11.94 | $11.98 | $11.68 | $11.78 | 1.67M |
| Sep 10, 2026 | $11.71 | $11.865 | $11.58 | $11.77 | 2.07M |
| Sep 9, 2026 | $12.09 | $12.18 | $11.745 | $11.92 | 6.16M |
| Sep 8, 2026 | $11.94 | $12.36 | $11.79 | $11.885 | 2.92M |
| Sep 4, 2026 | $11.47 | $11.85 | $11.37 | $11.83 | 1.26M |
| Sep 3, 2026 | $11.97 | $12.04 | $11.52 | $11.64 | 1.49M |
| Sep 2, 2026 | $11.71 | $12.04 | $11.605 | $11.81 | 2.18M |
| Sep 1, 2026 | $11.70 | $11.72 | $11.40 | $11.64 | 2.02M |
| Aug 31, 2026 | $11.59 | $11.615 | $11.455 | $11.56 | 1.67M |
| Aug 28, 2026 | $11.74 | $11.79 | $11.43 | $11.66 | 1.31M |
| Aug 27, 2026 | $11.60 | $11.89 | $11.55 | $11.74 | 1.37M |
| Aug 26, 2026 | $12.18 | $12.18 | $11.66 | $11.70 | 1.42M |
| Aug 25, 2026 | $11.66 | $11.675 | $11.45 | $11.64 | 1.05M |
| Aug 24, 2026 | $11.93 | $12.00 | $11.55 | $11.60 | 1.43M |
| Aug 21, 2026 | $11.92 | $11.99 | $11.682 | $11.95 | 1.21M |
| Aug 20, 2026 | $11.99 | $12.15 | $11.725 | $11.83 | 1.37M |
| Aug 19, 2026 | $11.75 | $12.255 | $11.60 | $12.15 | 2.06M |
| Aug 18, 2026 | $11.79 | $11.895 | $11.49 | $11.57 | 1.43M |
| Aug 17, 2026 | $11.49 | $11.88 | $11.43 | $11.87 | 1.59M |
| Aug 14, 2026 | $11.89 | $12.085 | $11.57 | $11.65 | 1.59M |
Latest NEOG news
The latest Smart Investors Daily articles mentioning NEOG.
Stock researchCompany · Overview
NEOG research
Overview
Company profile and research snapshot.
Company profile
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | Piper Sandler | Overweight | — |
| Aug 3, 2026 | Piper Sandler | Neutral | — |
| Jan 12, 2026 | Piper Sandler | Neutral | — |
| Jan 9, 2026 | Guggenheim | Buy | — |
| Dec 10, 2025 | CJS Securities | Market Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Neogen (NEOG) Following Sales Pressure And Higher Debt, Is The Rebound Already Priced In
Recent commentary around Neogen (NEOG) has focused on two pressure points for investors. Annual sales have declined for two years and returns on capital have shrunk, while a higher net debt to EBITDA ratio raises balance sheet sensitivity. The recent share price reflects that mixed picture. Neogen’s stock is up 29.5% on a 90 day share price return and 68.71% year to date, while the 1 year total shareholder return of 106.47% contrasts with a 3 year total shareholder return that has fallen...
Yahoo · Sep 3, 2026
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 3, 2026
1 Stock Under $50 with Promising Prospects and 2 We Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
